Literature DB >> 29547601

Nephrotoxicity: Evidence in Patients Receiving Cisplatin Therapy

Elizabeth A Duffy1, Wendy Fitzgerald2, Kelley Boyle3, Radha Rohatgi2.   

Abstract

BACKGROUND: Cisplatin has been used as a chemotherapeutic agent to treat many different cancers. A well-known side effect of cisplatin is nephrotoxicity, which is the primary dose-limiting toxicity. Hydration in conjunction with appropriate diuresis can decrease the incidence of nephrotoxicity.
OBJECTIVES: This article aims to identify best practices in supportive therapy for patients receiving cisplatin therapy.
METHODS: A team was assembled to review research-based evidence and summarize recommendations to address appropriate hydration regimens and forced diuresis for patients receiving cisplatin chemotherapy.
FINDINGS: After a systematic search of the literature, only one pediatric study was found. The remaining 22 research-based studies of adults were synthesized and critically appraised. Hydration is necessary to prevent nephrotoxicity with cisplatin administration. In addition, the administration of magnesium and mannitol may assist in maintaining renal function and reducing nephrotoxicity in adults receiving cisplatin. Additional research is needed to evaluate outcomes of these interventions in the pediatric population.

Entities:  

Keywords:  cancer; cisplatin; hydration; magnesium; mannitol; nephrotoxicity

Mesh:

Substances:

Year:  2018        PMID: 29547601     DOI: 10.1188/18.CJON.175-183

Source DB:  PubMed          Journal:  Clin J Oncol Nurs        ISSN: 1092-1095            Impact factor:   1.027


  9 in total

1.  Pre-treatment with Empagliflozin ameliorates Cisplatin induced acute kidney injury by suppressing apoptosis.

Authors:  Maaly A Abd Elmaaboud; Ahmed M Kabel; Mohamed Elrashidy
Journal:  J Appl Biomed       Date:  2019-02-06       Impact factor: 1.797

Review 2.  Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases.

Authors:  Dobrina Tsvetkova; Stefka Ivanova
Journal:  Molecules       Date:  2022-04-11       Impact factor: 4.927

3.  Preclinical Therapeutic Assessment of a New Chemotherapeutics [Dichloro(4,4'-Bis(2,2,3,3-Tetrafluoropropoxy) Methyl)-2,2'-Bipryridine) Platinum] in an Orthotopic Patient-Derived Xenograft Model of Triple-Negative Breast Cancers.

Authors:  Tzu-Chun Kan; Mei-Hsiang Lin; Chun-Chia Cheng; Jeng-Wei Lu; Ming-Thau Sheu; Yuan-Soon Ho; Sri Rahayu; Jungshan Chang
Journal:  Pharmaceutics       Date:  2022-04-11       Impact factor: 6.525

Review 4.  Natural products: potential treatments for cisplatin-induced nephrotoxicity.

Authors:  Chun-Yan Fang; Da-Yong Lou; Li-Qin Zhou; Jin-Cheng Wang; Bo Yang; Qiao-Jun He; Jia-Jia Wang; Qin-Jie Weng
Journal:  Acta Pharmacol Sin       Date:  2021-03-09       Impact factor: 7.169

5.  The abrupt pathological deterioration of cisplatin-induced acute kidney injury: Emerging of a critical time point.

Authors:  Qin Gong; Mulan Wang; Ya Jiang; Chengliang Zha; Dong Yu; Fan Lei; Yingying Luo; Yulin Feng; Shilin Yang; Jun Li; Lijun Du
Journal:  Pharmacol Res Perspect       Date:  2021-12

Review 6.  Mechanisms of Cisplatin Resistance in HPV Negative Head and Neck Squamous Cell Carcinomas.

Authors:  Ana Belén Griso; Lucía Acero-Riaguas; Beatriz Castelo; José Luis Cebrián-Carretero; Ana Sastre-Perona
Journal:  Cells       Date:  2022-02-05       Impact factor: 6.600

7.  Effect of dipeptidyl peptidase-4 inhibitors on cisplatin-induced acute nephrotoxicity in cancer patients with diabetes mellitus: A retrospective study.

Authors:  Takamasa Iwakura; Hirotaka Fukasawa; Atsushi Kitamura; Kento Ishibuchi; Hideo Yasuda; Ryuichi Furuya
Journal:  PLoS One       Date:  2020-02-21       Impact factor: 3.240

8.  Electrolytes supplementation can decrease the risk of nephrotoxicity in patients with solid tumors undergoing chemotherapy with cisplatin.

Authors:  Omary M S Minzi; Tatu E Lyimo; Francis F Furia; Alphonce I Marealle; Manase Kilonzi; George M Bwire; Christina Malichewe
Journal:  BMC Pharmacol Toxicol       Date:  2020-09-23       Impact factor: 2.483

Review 9.  Management of acute kidney injury in gastrointestinal tumor: An overview.

Authors:  Yi-Qi Su; Yi-Yi Yu; Bo Shen; Feng Yang; Yu-Xin Nie
Journal:  World J Clin Cases       Date:  2021-12-16       Impact factor: 1.337

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.